RNAi therapeutics are revolutionary within the methodology of there success, following a successful Phase I of Alnylam Pharmaceuticals RSV candidate what here is everyone thoughts on seeking FDA FastTrack status �. Thoughts here??? Toxicology and efficieny throughout preclinical data, with EVERY DRUG investigated, has thus far been AMAZING
You may read, but you can't write. You should proof read your statements before patting yourself on the back so much. Meticulously educated?? I personally believe ALNY has the possibility to become a life changing(financially)stock. Seldom, if at all, do you find a diamond in the rough in it's early phase. This company is on the cutting edge of something huge, RNAI. I don't have all my eggs in one basket, but I am wighted pretty heavy in this one. Good luck to all!
Jewell ALNY is easy.Take a look at Virexx-VIR on the Toronto.Pay special attention to the caliber of the scientist and their Phase III ovarian cancer drug Ovarex-United Therapeutics (UTP) is their partner.
What a finish, eh? Don't know about fast-track status. As it is one of the first human clinical trials with this type of therapeutic, it would be tough, in my opinion - especially since it is for RSV. If it was for pandemic flu, perhaps we could get fast-track approval.
To get fast track status their has to be a pressing need. RSV doesn't fit the bill. More to the point, this is a proof of principle clinical trial. I doubt managment would even apply for it. If safety is a problem, and by targeting RSV as number 1 trial they're hedging, fast track could kill this company. Glad I'm in though!!